scholarly journals Early iron overload in beta-thalassaemia major: when to start chelation therapy?

1982 ◽  
Vol 57 (12) ◽  
pp. 929-933 ◽  
Author(s):  
S Fargion ◽  
M T Taddei ◽  
V Gabutti ◽  
A Piga ◽  
A Di Palma ◽  
...  
Keyword(s):  
Iron Overload ◽  
Chelation Therapy ◽  
Thalassaemia Major ◽  
Beta Thalassaemia

scholarly journals A 15‐years follow‐up of deferasirox in beta‐thalassaemia major patients with iron overload

2020 ◽  
Vol 191 (3) ◽  
Author(s):  
Zhenbin Wei ◽  
Gaohui Yang ◽  
Yumei Huang ◽  
Peng Peng ◽  
Liling Long ◽  
...  
Keyword(s):  
Iron Overload ◽  
Thalassaemia Major ◽  
Beta Thalassaemia

Peripheral blood haematopoietic progenitor cells in patients with beta thalassaemia major receiving desferrioxamine or deferiprone as chelation therapy

2007 ◽  
Vol 78 (1) ◽  
pp. 48-51 ◽  
Author(s):  
Efthimia Vlachaki ◽  
Elissavet Ioannidou-Papagiannaki ◽  
Konstantinos Tziomalos ◽  
Styliani Haralambidou-Vranitsa ◽  
Vassilios Perifanis ◽  
...  
Keyword(s):  
Progenitor Cells ◽  
Peripheral Blood ◽  
Chelation Therapy ◽  
Thalassaemia Major ◽  
Beta Thalassaemia

Marrow proliferation as a cause of hearing loss in beta-thalassaemia major

2007 ◽  
Vol 122 (11) ◽  
pp. 1253-1256 ◽  
Author(s):  
D Thio ◽  
V Prasad ◽  
P Anslow ◽  
P Lennox
Keyword(s):  
Hearing Loss ◽  
Chelation Therapy ◽  
Disease Process ◽  
Iron Chelation ◽  
Ossicular Chain ◽  
Thalassaemia Major ◽  
Beta Thalassaemia ◽  
Marrow Expansion ◽  
Desferrioxamine Therapy ◽  
New Onset

AbstractObjective:The aim of this report was to highlight the fact that hearing loss in thalassaemia patients can be related to marrow expansion affecting the ossicles, resulting in a conductive loss.Case report:A six-year-old boy with transfusion-dependent beta-thalassaemia developed a unilateral hearing loss shortly after commencing desferrioxamine therapy. Otoxicity was assumed, but the deficit was later found to be of a conductive nature, due to marrow proliferation within the ossicular chain as a consequence of the disease process – a phenomenon previously unreported in the literature.Conclusion:It is important to elucidate the precise nature of new onset hearing loss in patients receiving iron chelation therapy, in order to avoid unnecessary cessation of much needed medication, on the assumption of ototoxicity.

Effects of dual chelation therapy with deferasirox and deferoxamine in patients with beta thalassaemia major

Vox Sanguinis ◽  
2022 ◽  
Author(s):  
Ahmad Zargari ◽  
Simon Wu ◽  
Anthea Greenway ◽  
Ken Cheng ◽  
Zane Kaplan
Keyword(s):  
Chelation Therapy ◽  
Thalassaemia Major ◽  
Beta Thalassaemia
Sign in / Sign up

Export Citation Format

Share Document